Linezolid: effectiveness and safety for approved and off-label indications (Q36967288)

17 August 2017

1 reference

title

Linezolid: effectiveness and safety for approved and off-label indications (English)

1 reference

17 August 2017

1 reference

3

Matthew E Falagas

1 reference

PubMed ID

17927491

17 August 2017

Konstantinos Z Vardakas

series ordinal

1

object named as

Konstantinos Z Vardakas

1 reference

17 August 2017

Fotinie Ntziora

2

1 reference

PubMed ID

17927491

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

1 reference

17 August 2017

8

1 reference

17 August 2017

14

1 reference

17 August 2017

2381-2400

1 reference

Epidemiology of methicillin-resistant Staphylococcus aureus

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

A multicenter evaluation of linezolid antimicrobial activity in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Efficacy of linezolid against methicillin-resistant or vancomycin-insensitive Staphylococcus aureus in a model of hematogenous pulmonary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

In vitro activity of linezolid against Gram-positive isolates causing infection in continuous ambulatory peritoneal dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Efficacy of linezolid in a staphylococcal endocarditis rabbit model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Mechanism of action of the oxazolidinone antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Oxazolidinones: a new class of antibacterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid-resistant enterococci: report of the first isolates in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Oxazolidinones: activity, mode of action, and mechanism of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

High Rate of Macrolide Resistance inStaphylococcus aureusStrains from Patients with Cystic Fibrosis Reveals High Proportions of Hypermutable Strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Clinical and microbiologic efficacy and safety profile of linezolid, a new oxazolidinone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Mechanisms of action of newer antibiotics for Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

In vitro susceptibilities of zygomycetes to conventional and new antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Clinical Pharmacokinetics of Linezolid, a Novel Oxazolidinone Antibacterial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

A review of linezolid: the first oxazolidinone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid penetration into osteo-articular tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Single dose pharmacokinetics of linezolid in infants and children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid pharmacokinetics in pediatric patients: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Use of linezolid in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Use of linezolid in children: an overview of recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Age and sex effects on the pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid in VAP by MRSA: a better choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Penetration of vancomycin into human lung tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid and vancomycin for methicillin-resistant Staphylococcus aureus nosocomial pneumonia: the subtleties of subgroup analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Unresolved questions with the use of linezolid vs vancomycin for nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Early experience with linezolid for infections in orthopaedics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid for the treatment of adults with bone and joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid for the treatment of patients with central nervous system infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Vancomycin-induced immune thrombocytopenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid-associated toxic optic neuropathy: a report of 2 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid use associated with lactic acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

A comparative study on the cost of new antibiotics and drugs of other therapeutic categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

21 January 2018

Oxazolidinones: a review

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2381

10.1517/14656566.8.14.2381

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17927491